Bradley Augustson
Overview
Explore the profile of Bradley Augustson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Popat R, Augustson B, Gironella M, Lee C, Cannell P, Patel N, et al.
Blood Cancer J
. 2024 Oct;
14(1):184.
PMID: 39433730
No abstract available.
2.
Fasser D, Lewis K, Leslie C, Cull G, Radeski D, Augustson B, et al.
Leuk Lymphoma
. 2024 Oct;
66(2):345-348.
PMID: 39421976
No abstract available.
3.
Irving A, Petrie D, Harris A, Fanning L, Wood E, Moore E, et al.
PLoS One
. 2024 Aug;
19(8):e0308812.
PMID: 39190684
Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem...
4.
Ninkovic S, Harrison S, Lee J, Murphy N, Lee J, Estell J, et al.
Haematologica
. 2024 Jan;
109(7):2229-2238.
PMID: 38235519
This multicenter, phase II study of the Australasian Lymphoma and Leukemia Group and the Asian Myeloma Network investigated fixed-duration (18-month) treatment with carfilzomib (K), thalidomide (T), and dexamethasone (d) (KTd)...
5.
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, et al.
Br J Haematol
. 2022 Jul;
198(5):830-837.
PMID: 35818641
The frequency and causes of early mortality in patients with newly diagnosed multiple myeloma (NDMM) have not been well described in the era of novel agents. We investigated early mortality...
6.
Dimopoulos M, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, et al.
Am J Hematol
. 2022 May;
98(1):E15-E19.
PMID: 35604280
No abstract available.
7.
Creeper K, Augustson B, Kusel K, Fulham M, Ho J, Quach H, et al.
Intern Med J
. 2021 Oct;
51(10):1707-1712.
PMID: 34664367
Imaging modalities for multiple myeloma (MM) have evolved to enable earlier detection of disease. Furthermore, the diagnosis of MM requiring therapy has recently changed to include disease prior to bone...
8.
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison S, et al.
Bone Marrow Transplant
. 2021 May;
56(10):2533-2543.
PMID: 34011965
Supported by clinical trial proven survival benefit, clinical guidelines recommend upfront autologous stem cell transplantation (ASCT) for eligible MM patients. However, reported real-world utilisation is lower than expected (40-60%). We...
9.
Rees M, Mollee P, Ng J, Murton A, Gonsalves J, Panigrahi A, et al.
Bone Marrow Transplant
. 2021 Apr;
56(9):2152-2159.
PMID: 33911199
G-CSF only mobilisation has been shown to enhance immune reconstitution early post-transplant, but its impact on survival remains uncertain. We undertook a retrospective review of 12 transplant centres to examine...
10.
Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira M, Kwok F, et al.
J Clin Oncol
. 2020 Jul;
38(28):3252-3260.
PMID: 32730181
Purpose: Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents...